China Authorizes New Inactivated Vaccine Amid Doubt Over Sinopharm Jabs
Efficacy In New Spotlight In Seychelles
A new emergency authorization marks China’s fourth approval for inactivated COVID-19 vaccines, despite lingering doubts over the protection offered by the technology and surging cases in one of the most vaccinated countries where Sinopharm’s inactivated vaccines are widely used.
You may also be interested in...
As the B.1.617 variant of SARS-CoV-2 spreads to countries including the UK and US after having caused havoc in India, vaccine effectiveness against this variant is under the lens with breakthrough cases reported post full vaccination. Meanwhile, CEPI’s offer to help in testing against variants has potential to harmonize assessment of COVID-19 vaccines performance.
While new legislation has pushed prescription drug pricing high up the political agenda for US lawmakers, the issue has also come into the spotlight again for Chinese regulators, which have just launched new investigations into two officials. While the two countries are taking drastically different routes to tackling pricing, the developments show compliance risks remain high in China.
The antibody-drug conjugate market is emerging as the next battleground for intense competition in China, with global partnerships becoming essential to win, as evidenced by a major new alliance between Innovent and Sanofi.